Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04517851 · ClinicalTrials.gov registry record · Phase 2
Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis
A Phase 2 study of Primary Myelofibrosis and Myelofibrosis Transformation in Essential Thrombocythemia, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT04517851 is a Phase 2 study of Primary Myelofibrosis and Myelofibrosis Transformation in Essential Thrombocythemia that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 15 participants, below the 120-participant average among 30 other Primary Myelofibrosis trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04517851, a Phase 2 study of Primary Myelofibrosis and Myelofibrosis Transformation in Essential Thrombocythemia, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial investigates how well elotuzumab works in treating patients with JAK2-mutated myelofibrosis. Elotuzumab may help to control myelofibrosis and/or help to improve blood cell count and bone marrow function.
Conditions Studied
Interventions
- OTHER Questionnaire Administration
- BIOLOGICAL Elotuzumab
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2021-02-10 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04517851
The ClinicalTrials.gov registry entry for NCT04517851 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 120-participant average among 30 other Primary Myelofibrosis trials with a reported enrollment target (87% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Primary Myelofibrosis appearing as the primary indexed condition, and to 2 interventions - of which Questionnaire Administration is the first listed.
NCT04517851 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT04517851 about?
NCT04517851 is a clinical study titled "Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis". This phase II trial investigates how well elotuzumab works in treating patients with JAK2-mutated myelofibrosis. Elotuzumab may help to control myelofibrosis and/or help to improve blood cell count and bone marrow function.
What is the current status of trial NCT04517851?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2021-02-10. Estimated completion is 2027-12-31.
What conditions does trial NCT04517851 study?
This clinical trial studies the following conditions: Primary Myelofibrosis, Myelofibrosis Transformation in Essential Thrombocythemia, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase.
What interventions are being tested in trial NCT04517851?
The interventions under investigation include: Questionnaire Administration (OTHER), Elotuzumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT04517851?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04517851 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Myelofibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis
RECRUITING · Phase 2
-
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
RECRUITING · Phase 2
-
Study of Canakinumab in Patients With Myelofibrosis
RECRUITING · Phase 2
-
Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
RECRUITING · Phase 2
-
Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes
RECRUITING · Phase 2
-
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
RECRUITING · Phase 2
Explore more on PlainTrial
Primary Myelofibrosis
All registered trials for this condition
Myelofibrosis Transformation in Essential Thrombocythemia
All registered trials for this condition
Texas
All trials with a study site in Texas
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.